1. Home
  2. AKBA vs FCBC Comparison

AKBA vs FCBC Comparison

Compare AKBA & FCBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • FCBC
  • Stock Information
  • Founded
  • AKBA 2007
  • FCBC 1874
  • Country
  • AKBA United States
  • FCBC United States
  • Employees
  • AKBA N/A
  • FCBC N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • FCBC Major Banks
  • Sector
  • AKBA Health Care
  • FCBC Finance
  • Exchange
  • AKBA Nasdaq
  • FCBC Nasdaq
  • Market Cap
  • AKBA 861.7M
  • FCBC 737.6M
  • IPO Year
  • AKBA 2014
  • FCBC 1992
  • Fundamental
  • Price
  • AKBA $3.04
  • FCBC $36.18
  • Analyst Decision
  • AKBA Strong Buy
  • FCBC
  • Analyst Count
  • AKBA 5
  • FCBC 0
  • Target Price
  • AKBA $6.90
  • FCBC N/A
  • AVG Volume (30 Days)
  • AKBA 4.0M
  • FCBC 38.3K
  • Earning Date
  • AKBA 08-07-2025
  • FCBC 07-22-2025
  • Dividend Yield
  • AKBA N/A
  • FCBC 3.43%
  • EPS Growth
  • AKBA N/A
  • FCBC N/A
  • EPS
  • AKBA N/A
  • FCBC 2.72
  • Revenue
  • AKBA $203,733,000.00
  • FCBC $162,762,000.00
  • Revenue This Year
  • AKBA $27.95
  • FCBC $2.34
  • Revenue Next Year
  • AKBA $43.88
  • FCBC $1.10
  • P/E Ratio
  • AKBA N/A
  • FCBC $13.29
  • Revenue Growth
  • AKBA 16.75
  • FCBC N/A
  • 52 Week Low
  • AKBA $1.24
  • FCBC $32.81
  • 52 Week High
  • AKBA $4.08
  • FCBC $49.02
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 34.84
  • FCBC 41.12
  • Support Level
  • AKBA $2.92
  • FCBC $34.83
  • Resistance Level
  • AKBA $3.44
  • FCBC $37.39
  • Average True Range (ATR)
  • AKBA 0.15
  • FCBC 1.13
  • MACD
  • AKBA -0.06
  • FCBC 0.08
  • Stochastic Oscillator
  • AKBA 13.79
  • FCBC 73.58

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About FCBC First Community Bankshares Inc. (VA)

First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.

Share on Social Networks: